{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:04:01Z","timestamp":1789513441221,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clon.2026.104204","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:38:47Z","timestamp":1779583127000},"page":"104204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Proton Radiotherapy with Induction Chemotherapy for Locally Advanced Pancreatic Cancer: A Retrospective Analysis of Treatment Strategy and Outcomes"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5604-1852","authenticated-orcid":false,"given":"K.","family":"Terashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9991-8512","authenticated-orcid":false,"given":"K.","family":"Ami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0092-6615","authenticated-orcid":false,"given":"Y.","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2321-6165","authenticated-orcid":false,"given":"R.","family":"Bessho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.S.","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4465-4300","authenticated-orcid":false,"given":"Y.","family":"Demizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fukumitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0360-8460","authenticated-orcid":false,"given":"H.","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4947-7665","authenticated-orcid":false,"given":"S.","family":"Tokumaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2026.104204_bib1","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clon.2026.104204_bib2","first-page":"607","volume":"378","author":"Vincent","year":"2011","journal-title":"Pancreat Cancer Lancet"},{"key":"10.1016\/j.clon.2026.104204_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clon.2026.104204_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","article-title":"Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study","volume":"5","author":"Philip","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clon.2026.104204_bib5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/jjco\/hyab014","article-title":"The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer","volume":"51","author":"Takeda","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clon.2026.104204_bib6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2026.104204_bib7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pan.2019.01.001","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan","volume":"19","author":"Matsumoto","year":"2019","journal-title":"Pancreatology"},{"key":"10.1016\/j.clon.2026.104204_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","article-title":"A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)","volume":"181","author":"Ozaka","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2026.104204_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ags3.12613","article-title":"Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: results of a dual-center study","volume":"7","author":"Igarashi","year":"2023","journal-title":"Ann Gastroenterol Surg"},{"key":"10.1016\/j.clon.2026.104204_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jhbp.1050","article-title":"Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy","volume":"30","author":"Lee","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.clon.2026.104204_bib11","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/j.asjsur.2023.03.162","article-title":"Predicting conversion surgery in patients with locally advanced pancreatic cancer after modified FOLFIRINOX treatment","volume":"46","author":"Ninomiya","year":"2023","journal-title":"Asian J Surg"},{"key":"10.1016\/j.clon.2026.104204_bib12","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.ijrobp.2012.02.051","article-title":"A phase I\/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer","volume":"84","author":"Ben-Josef","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104204_bib13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","article-title":"Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial","volume":"14","author":"Mukherjee","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2026.104204_bib14","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of Chemoradiotherapy vs Chemotherapy on survival in patients With locally advanced Pancreatic Cancer controlled after 4 months of Gemcitabine with or without Erlotinib: The LAP07 Randomized Clinical Trial","volume":"315","author":"Hammel","year":"2016","journal-title":"Jama"},{"key":"10.1016\/j.clon.2026.104204_bib15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2006.09.7816","article-title":"Particle radiation therapy using proton and heavier ion beams","volume":"25","author":"Schulz-Ertner","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2026.104204_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.radonc.2011.12.029","article-title":"A phase I\/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis","volume":"103","author":"Terashima","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2026.104204_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13014-022-02001-w","article-title":"Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study","volume":"17","author":"Ogura","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2026.104204_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818783879","article-title":"Effectiveness and safety of Simultaneous Integrated Boost-Proton Beam Therapy for localized Pancreatic Cancer","volume":"17","author":"Kim","year":"2018","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.clon.2026.104204_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2019.03.012","article-title":"Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer","volume":"136","author":"Hiroshima","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2026.104204_bib20","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.21037\/jgo-22-327","article-title":"A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer","volume":"13","author":"Sanghvi","year":"2022","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.clon.2026.104204_bib21","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ijrobp.2018.04.057","article-title":"Multi-institutional study of carbon-ion Radiotherapy for locally Advanced Pancreatic Cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1403 Pancreas","volume":"101","author":"Kawashiro","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104204_bib22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.radonc.2018.08.026","article-title":"A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer","volume":"129","author":"Shinoto","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2026.104204_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102857","article-title":"Carbon-ion Radiotherapy combined with concurrent Chemotherapy for Locally Advanced Pancreatic Cancer: a Retrospective Case Series Analysis","volume":"15","author":"Okamoto","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.clon.2026.104204_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2026.104204_bib25","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0360-3016(02)02949-8","article-title":"Preclinical biological assessment of proton and carbon ion beams at Hyogo Ion Beam Medical Center","volume":"54","author":"Kagawa","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104204_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78875-1","article-title":"Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.clon.2026.104204_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00280-012-1918-7","article-title":"Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer","volume":"70","author":"Kim","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clon.2026.104204_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cncr.22735","article-title":"Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy","volume":"110","author":"Krishnan","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2026.104204_bib29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2006.07.5663","article-title":"Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies","volume":"25","author":"Huguet","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2026.104204_bib30","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of Chemoradiotherapy vs Chemotherapy on survival in patients with Locally Advanced Pancreatic Cancer controlled after 4 months of Gemcitabine with or without Erlotinib: The LAP07 Randomized Clinical Trial","volume":"315","author":"Hammel","year":"2016","journal-title":"Jama"},{"key":"10.1016\/j.clon.2026.104204_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jjco\/hyaa198","article-title":"Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106","volume":"51","author":"Ioka","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clon.2026.104204_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070981","article-title":"Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review","volume":"11","author":"Napolitano","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.clon.2026.104204_bib33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ags3.12295","article-title":"Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma","volume":"4","author":"Satoi","year":"2020","journal-title":"Ann Gastroenterol Surg"},{"key":"10.1016\/j.clon.2026.104204_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061428","article-title":"Benefits of conversion surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma","volume":"12","author":"Yanagimoto","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.clon.2026.104204_bib35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/ags3.12468","article-title":"Salvage hepatectomy for local recurrence after particle therapy using proton and carbon ion beams for liver cancer","volume":"5","author":"Tanaka","year":"2021","journal-title":"Ann Gastroenterol Surg"},{"key":"10.1016\/j.clon.2026.104204_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0958-3947(01)00072-3","article-title":"Comparative treatment planning between proton and X-ray therapy in pancreatic cancer","volume":"26","author":"Hsiung-Stripp","year":"2001","journal-title":"Med Dosim"},{"key":"10.1016\/j.clon.2026.104204_bib37","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis","volume":"126","author":"Tchelebi","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2026.104204_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13014-023-02301-9","article-title":"Proton radiotherapy as a treatment strategy to increase survival in locally advanced pancreatic cancer in the body and tail: a retrospective study","volume":"18","author":"Ami","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2026.104204_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13014-020-01731-z","article-title":"Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results","volume":"16","author":"Lee","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2026.104204_bib40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/XCS.0000000000000873","article-title":"Innovative Combination Treatment to Expand the Indications of Particle Therapy: Spacer Placement Surgery Using Bio-Absorbable Polyglycolic Acid Spacer","volume":"238","author":"Komatsu","year":"2024","journal-title":"J Am Coll Surg"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526001755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526001755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:40:32Z","timestamp":1789512032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526001755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"alternative-id":["S0936655526001755"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104204","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proton Radiotherapy with Induction Chemotherapy for Locally Advanced Pancreatic Cancer: A Retrospective Analysis of Treatment Strategy and Outcomes","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104204"}}